2026年7月20日，歌礼制药-B发布翌日披露报表。公告显示，公司于当日于香港联交所场内回购普通股10.00万股，约占已发行股本的0.0094%。每股回购价格介乎8.61港元至9.02港元，合计耗资约88.13万港元。
根据公告，截至2026年7月20日，公司已发行股本为10.61亿股，库存股数量708.42万股，合计股份总数约10.68亿股。此次回购股份在日后完成注销后将不再计入已发行股份。公司获股东大会于2026年6月29日通过的回购授权，可回购股份总数为10.61亿股，至今已累计在交易所以及其他证券交易所回购114.50万股，占授权通过时已发行股本的约0.1079%。
公告同时显示，公司确认已遵守香港联交所证券上市规则及相关法律法规。本次公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.